双特异性抗体治疗复发/难治性弥漫大B细胞淋巴瘤的研究进展

doi:10.3969/j.issn.1004-583X.2025.09.014

摘要/Abstract

摘要：

弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma DLBCL)是最常见的非霍奇金淋巴瘤亚型,约30%~40%患者经一线治疗后发展为复发/难治性(R/R)DLBCL,临床预后差,亟需有效治疗策略。双特异性抗体(bispecific antibody, BsAb)作为一种新型免疫疗法,通过同时靶向肿瘤细胞抗原(如CD20)和T细胞表面CD3,激活T细胞介导的肿瘤细胞杀伤作用,为R/R DLBCL提供了新的治疗选择。本文对BsAb治疗DLBCL的作用机制、疗效和毒性进行综述,重点关注处于研发前沿的靶向CD20/CD3 BsAb,旨在为后续临床决策及试验设计提供参考与启示。

关键词: 双特异性抗体, 弥漫大B细胞淋巴瘤, 复发, 难治

中图分类号:

R733.4

佘明金, 冯三丽, 吴亚运, 程蒙蒙, 高琳. 双特异性抗体治疗复发/难治性弥漫大B细胞淋巴瘤的研究进展[J]. 临床荟萃, 2025, 40(9): 855-860.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.09.014

https://www.lchc.cn/CN/Y2025/V40/I9/855

图/表 2

参考文献 36

[1]	Sehn LH, Salles G. Diffuse large B-cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858.doi: 10.1056/NEJMra2027612.
[2]	Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study[J]. Blood, 2017, 130(16): 1800-1808.doi:10.1182/blood-2017-03-769620. pmid: 28774879
[3]	Siddiqi T. CARs vs bispecifics: The race is on![J]. Blood, 2024, 144(6): 592-593. doi: 10.1182/blood.2024025130. pmid: 39115828
[4]	李青, 邓琦. 嵌合抗原受体T细胞治疗复发难治弥漫大B细胞淋巴瘤进展[J]. 临床荟萃, 2022, 37(2): 182-187.doi:3969/j.issn.1004-583X.2022.02.018.
[5]	Ahmed G, Furqan F, Nasrollahi E, et al. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma[J]. Expert Rev Anticancer Ther, 2024, 24(8): 705-715.doi:10.1080/14737140.
[6]	Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: Opportunities and challenges[J]. Nat Rev Clin Oncol, 2024, 21(7): 539-560.doi:10.1038/s41571-024-00905-y.
[7]	Doraiswamy A, Shah MR, Bannerji R. Immunotherapies old and new: Hematopoietic stem cell transplant, chimeric antigen receptor T cells, and bispecific antibodies for the treatment of relapsed/refractory diffuse large B cell lymphoma[J]. Curr Hematol Malig Rep, 2021, 16(1): 72-81.doi: 10.1007/s11899-021-00610-y.
[8]	Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma[J]. Haematologica, 2025, 110(7): 1483-1499..doi:10.3324/haematol.2024.285343.
[9]	Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities[J]. Blood, 2023, 141(5): 467-480.doi:10.1182/blood.2021011994.
[10]	van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment[J]. Blood Cancer J, 2021, 11(2): 38.doi: 10.1038/s41408-021-00430-6.
[11]	Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study[J]. Lancet, 2021, 398(10306): 1157-1169.doi:10.1016/S0140-6736(21)00889-8. pmid: 34508654
[12]	Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2023, 41(12): 2238-2247.doi: 10.1200/JCO.22.01725.
[13]	Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody[J]. Leuk Lymphoma, 2021, 62(13): 3098-3108.doi: 10.1080/10428194.
[14]	Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2022, 387(24): 2220-2231.doi: 10.1056/NEJMoa2206913.
[15]	Birtas Atesoglu E, Gulbas Z, Uzay A, et al. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data[J]. Hematol Oncol, 2023, 41(4): 663-673..doi: 10.1002/hon.3174.
[16]	中国临床肿瘤学会淋巴瘤专家委员会. 格菲妥单抗治疗弥漫大B细胞淋巴瘤临床用药指导原则(2024年版)[J]. 白血病·淋巴瘤, 2024, 33(5): 257-264.doi: 10.3760/cma.j.cn115356-20240205-00020.
[17]	Kang C. Mosunetuzumab: First approval[J]. Drugs, 2022, 82(11): 1229-1234.doi: 10.1007/s40265-022-01713-3. pmid: 35947358
[18]	Bartlett NL, Assouline S, Giri P, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma[J]. Blood Adv, 2023, 7(17): 4926-4935.doi: 10.1182/bloodadvances.2022009260. pmid: 37067952
[19]	Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma[J]. Blood, 2016, 127(11): 1410-1416.doi: 10.1182/blood-2015-06-651380. pmid: 26755709
[20]	Hou JZ, Jacobs R, Cho SG, et al. Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) B-NHL[J]. Blood, 2022, 140(Supplement 1): 1474-1475.doi:10.1182/blood-2022-166385.
[21]	Patel K, Riedell PA, Tilly H, et al. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-hodgkin's lymphoma: Recommended dose safety/efficacy update and escalation exposure-response analysis[J]. Blood, 2022, 140(Supplement 1): 9470-9472.doi:10.1182/blood-2022-159586.
[22]	Budde E, Gopal AK, Flinn IW, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136(Supplement 1): 45-46.doi:10.1182/blood-2020-134983.
[23]	Song Y, Li Z, Li L, et al. GB261, an Fc-function enabled and CD3 affinity de-tuned CD20/CD3 bispecific antibody, demonstrated a highly advantageous safety/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed/refractory non-Hodgkin lymphoma[J]. Blood, 2023, 142(Supplement 1): 1719-1719.doi:10.1182/blood-2023-188444.
[24]	Lu H, Oka A, Coulson M, et al. PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies[J]. Blood, 2022, 140(Supplement 1): 3148-3148.doi:10.1182/blood-2022-168904.
[25]	Meetze K, Mehta NK, Li B, et al. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression[J]. J Immunother Cancer, 2023, 11(8):e007398. doi: 10.1136/jitc-2023-007398.
[26]	Piccione EC, Juarez S, Liu J, et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells[J]. MAbs, 2015, 7(5): 946-956.doi: 10.1080/19420862.2015.1062192. pmid: 26083076
[27]	Zhu D, Hadjivassiliou H, Jennings C, et al. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional Fc, selectively targets and depletes non-Hodgkin's lymphoma[J]. MAbs, 2024, 16(1): 2310248.doi: 10.1080/19420862.2024.2310248.
[28]	Cassanello G, Luna de Abia A, Falchi L. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma[J]. Oncoimmunology, 2024, 13(1): 2321648.doi: 10.1080/2162402X.2024.2321648.
[29]	Kim J, Cho J, Lee MH, et al. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis[J]. Blood, 2024, 144(6): 629-638. doi: 10.1182/blood.2023023419.
[30]	Brooks TR, Caimi PF. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma[J]. Blood Rev, 2024, 63: 101140.doi: 10.1016/j.blre.2023.101140.
[31]	Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas[J]. Blood Cancer J, 2024, 14(1): 27.doi: 10.1038/s41408-024-00997-w.
[32]	Herrera M, Pretelli G, Desai J, et al. Bispecific antibodies: advancing precision oncology[J]. Trends Cancer, 2024, 10(10): 893-919.doi: 10.1016/j.trecan.2024.07.002.
[33]	Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma[J]. Hematology Am Soc Hematol Educ Program, 2023, 2023(1): 332-339.doi:10.1182/hematology.2023000433. pmid: 38066842
[34]	Wei J, Zheng H, Dai S, et al. A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023[J]. Heliyon, 2024, 10(2): e23929.doi: 10.1016/j.heliyon.2023.e23929.
[35]	Brody JD, Jørgensen J, Belada D, et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial[J]. Blood, 2025, 145(15): 1621-1631.doi: 10.1182/blood.2024026830.
[36]	Long M, Mims AS, Li Z. Factors affecting the cancer immunotherapeutic efficacy of T cell bispecific antibodies and strategies for improvement[J]. Immunol Invest, 2022, 51(8): 2176-2214. doi: 10.1080/08820139.2022.2131569.

双特异性抗体治疗复发/难治性弥漫大B细胞淋巴瘤的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李登峰, 黄家虎, 李廷俊, 吕勇, 金珍珍, 连少峰. 基于肺部超声评分的儿童难治性肺炎支原体肺炎预测模型的构建[J]. 临床荟萃, 2025, 40(2): 153-157.
[2]	申帅洁, 陈荣梯, 朱嵩, 平芬. 乳酸脱氢酶在难治性肺炎支原体肺炎中的临床应用进展[J]. 临床荟萃, 2025, 40(2): 185-188.
[3]	邬晓敏, 方益鹏, 章真, 章烨, 金成. 仑伐替尼联合PD-1单抗及GEMOX方案在晚期胆道恶性肿瘤治疗中的临床观察[J]. 临床荟萃, 2024, 39(5): 408-412.
[4]	徐文灯, 沈懿, 张小峰. 心电图非特异性ST-T异常与急性缺血性脑卒中复发的相关性[J]. 临床荟萃, 2023, 38(10): 883-886.
[5]	王晶霞, 汤灵玲. 肠道微生物群疗法防治复发性艰难梭菌感染研究进展[J]. 临床荟萃, 2022, 37(8): 759-763.
[6]	周耀, 魏博涛. 锌辅助治疗小儿轮状病毒肠炎及对短期复发影响的Meta分析[J]. 临床荟萃, 2022, 37(2): 106-113.
[7]	李青, 邓琦. 嵌合抗原受体T细胞治疗复发难治弥漫大B细胞淋巴瘤进展[J]. 临床荟萃, 2022, 37(2): 182-187.
[8]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[9]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[10]	王延旭，刘苗，张瑞星. Ⅳ型胃神经内分泌肿瘤的临床病理特征及影响术后复发的危险因素分析[J]. 临床荟萃, 2020, 35(9): 805-810.
[11]	郑涵露, 赵小英. CD5阳性弥漫大B细胞淋巴瘤研究进展[J]. 临床荟萃, 2020, 35(3): 282-288.
[12]	赵学刚1，刘晓敏1，李丽1，周炜2. 肌骨超声检查对临床缓解类风湿关节炎患者疾病复发的预测价值[J]. 临床荟萃, 2019, 34(9): 802-804.
[13]	诺扎·代尼尔，木胡牙提. 心房颤动射频消融术后复发影响因素的荟萃分析[J]. 临床荟萃, 2019, 34(3): 267-272.
[14]	刘方, 张学军, 牛志云, 温树鹏, 王颖, 王福旭. 异基因造血干细胞移植后嵌合状态与白血病复发关系的研究[J]. 临床荟萃, 2019, 34(12): 1076-1080.
[15]	杨婷婷1，王艳艳1，王宝宏2. 外周血淋巴细胞和单核细胞比值对预测弥漫大B细胞淋巴瘤复发的研究[J]. 临床荟萃, 2019, 34(12): 1089-1093.